Compare Home Depot Inc (HD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Sana Biotechnology Inc — how do they compare? Home Depot Inc trades at $291.42 (market cap $294.79B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Home Depot Inc is far larger — about 352.3× Sana Biotechnology Inc's market cap, and Home Depot Inc pays a 3.15% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HD | SANA | |
|---|---|---|
Market Cap | $294.79B | $836.71M |
Volume | 8,693,917 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $5.92 |
52-Week Low | $281.15 | $2.68 |
Typical Hold Time | 139 Days | — |
Enterprise Value | $355.27B | $749.96M |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $291.17, up 1.89% today, with a bullish technical signal but mixed moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.92 exceeding expectations. Revenue for 2025 reached $159.51 billion, though net income margin has trended down to 8.41%. Analyst consensus is bullish with a $379.93 price target, but rising mortgage rates and weak big-ticket demand pose headwinds.
The outlook remains cautiously optimistic given HD's robust profitability and Pro business growth, but margin pressure and housing market sensitivity are key risks. Institutional activity shows mixed positioning, with some firms increasing stakes while others trim holdings. The stock's valuation at a P/E of 20.68 appears reasonable if earnings momentum continues.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
